Literature DB >> 6239876

Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation.

A B Federici, J H Elder, L De Marco, Z M Ruggeri, T S Zimmerman.   

Abstract

To better define the role of carbohydrate in the structure and ristocetin cofactor activity of von Willebrand factor, we have removed up to 83% of total hexose by sequential treatment of the molecule with endo-beta-N-acetyl-glucosaminidase F (endo F), neuraminidase, and beta-galactosidase. Endo F alone removed 69% of total hexose and D-galactose, and 71% of sialic acid. However, there was no discernible loss of large multimers and the ristocetin cofactor activity was decreased by only 11%. The reduced von Willebrand factor subunit migrated more rapidly in polyacrylamide gels containing SDS, consistent with a 10% decrease of molecular mass. All multimers of unreduced carbohydrate-modified von Willebrand factor migrated more rapidly in SDS-agarose, but the triplet pattern of individual multimers was unchanged. This alteration in multimer migration rate did not resemble alterations found so far in von Willebrand disease variants. Further treatment of von Willebrand factor with neuraminidase and beta-galactosidase reduced the D-galactose to 15% and ristocetin cofactor activity to 57%. A similar decrease in ristocetin cofactor activity was seen if von Willebrand factor was treated only with neuraminidase and beta-galactosidase. In contrast, treating von Willebrand factor with neuraminidase and beta-galactosidase in the presence of protease inhibitors (20 mM benzamidine, 20 U/ml aprotonin, 15 micrograms/ml leupeptin) resulted in a comparable removal of carbohydrate with no change in ristocetin cofactor activity. Moreover, the multimeric structure remained intact in spite of 80% removal of D-galactose. This suggested that carbohydrate was protecting von Willebrand factor against traces of one or more protease contaminants. Evidence in support of this hypothesis was obtained by exposing von Willebrand factor to plasmin after pretreatment with neuraminidase alone or with neuraminidase and beta-galactosidase. A loss of large multimers was observed from von Willebrand factor that had been pretreated with neuraminidase, but this was even greater if pretreatment was also with beta-galactosidase. In contrast, the multimeric structure of von Willebrand factor with intact carbohydrate was not affected by plasmin under similar conditions. These studies suggest that carbohydrate protects von Willebrand factor from disaggregation occurring secondarily to proteolytic attack but does not play a direct role in maintaining its multimeric structure or ristocetin cofactor activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6239876      PMCID: PMC425394          DOI: 10.1172/JCI111628

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  The effects of neuraminidase treatment on the biological activities of factor VIII.

Authors:  L Rosenfeld; E P Kirby
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

2.  "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.

Authors:  W N Burnette
Journal:  Anal Biochem       Date:  1981-04       Impact factor: 3.365

3.  Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

4.  Effect of multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets.

Authors:  H R Gralnick; S B Williams; D K Morisato
Journal:  Blood       Date:  1981-08       Impact factor: 22.113

5.  Carbohydrates selectively protect a specific domain of fibronectin against proteases.

Authors:  B A Bernard; K M Yamada; K Olden
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

6.  Carbohydrate on human factor VIII/von Willebrand factor. Impairment of function by removal of specific galactose residues.

Authors:  J M Sodetz; J C Paulson; S V Pizzo; P A McKee
Journal:  J Biol Chem       Date:  1978-10-25       Impact factor: 5.157

7.  Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC).

Authors:  Z M Ruggeri; I M Nilsson; R Lombardi; L Holmberg; T S Zimmerman
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

8.  The complex multimeric composition of factor VIII/von Willebrand factor.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  Blood       Date:  1981-06       Impact factor: 22.113

9.  Quantitation of binding of factor VIII antigen to concanavalin A.

Authors:  M A Howard; J Perkin; J Koutts; B G Firkin
Journal:  Br J Haematol       Date:  1981-04       Impact factor: 6.998

10.  Characterization of the defect of the factor VIII/von Willebrand factor protein in von Willebrand's disease.

Authors:  H R Gralnick; M C Cregger; S B Williams
Journal:  Blood       Date:  1982-03       Impact factor: 22.113

View more
  8 in total

1.  Characterization of von Willebrand factor in primary pulmonary hypertension.

Authors:  M T Collados; J Sandoval; S López; F A Massó; A Páez; J R Borbolla; L F Montaño
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

2.  Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.

Authors:  J A Dent; S D Berkowitz; J Ware; C K Kasper; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

3.  Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor.

Authors:  B Samor; J C Michalski; C Mazurier; M Goudemand; P De Waard; J F Vliegenthart; G Strecker; J Montreuil
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

4.  Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands.

Authors:  Lesley G Ellies; David Ditto; Gallia G Levy; Mark Wahrenbrock; David Ginsburg; Ajit Varki; Dzung T Le; Jamey D Marth
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-03       Impact factor: 11.205

5.  Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation.

Authors:  L De Marco; A Girolami; S Russell; Z M Ruggeri
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

6.  Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin.

Authors:  S D Berkowitz; J Dent; J Roberts; Y Fujimura; E F Plow; K Titani; Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

7.  von Willebrand factor synthesized by endothelial cells from a patient with type IIB von Willebrand disease supports platelet adhesion normally but has an increased affinity for platelets.

Authors:  P G de Groot; A B Federici; H C de Boer; P d'Alessio; P M Mannucci; J J Sixma
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications.

Authors:  Massimo Franchini; Franco Capra; Giovanni Targher; Martina Montagnana; Giuseppe Lippi
Journal:  Thromb J       Date:  2007-09-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.